Immutep Receives Significant R&D Tax Incentive
Immutep Limited (ASX: IMM; NASDAQ: IMMP), an innovative biotechnology company, is proud to announce a remarkable achievement in securing a substantial research and development tax incentive from the French government. This financial support totals €2,588,954, which is approximately A$4,567,769. This incentive is granted under France's Crédit d’Impôt Recherche scheme, a vital initiative designed to assist companies that are actively engaged in research and development within Europe.
Understanding the Research Tax Credit
The French government has implemented the Crédit d’Impôt Recherche (CIR) to encourage research initiatives among companies. It allows firms to receive reimbursements of up to 30% on eligible research and development expenditures. This program is pivotal for fostering innovation in technology and science, enabling businesses like Immutep to thrive.
How Immutep Qualifies for the Incentive
Immutep qualifies for this substantial CIR tax incentive through its dedicated subsidiary, Immutep S.A.S., which conducts research activities in its laboratory located in France. This innovative work is critical for the ongoing development of therapies that target cancer and autoimmune diseases. The funds from this tax incentive will be directly allocated to expenses related to R&D endeavors done in the European Union during the specified year.
Combining Global Support for Development
In addition to the French tax incentive, Immutep is also positioned to benefit from the Australian Federal Government's R&D tax incentive program. This dual support highlights the company's international commitment to advancing medical research and development. It allows Immutep to substantiate its innovative therapies while continuing to uphold rigorous standards of scientific inquiry.
Funding Future Clinical Developments
The newly acquired funding will significantly bolster Immutep's ongoing and future clinical trials for its promising therapeutic candidates, eftilagimod alfa and IMP761. Both of these projects represent the forefront of immunotherapy, aiming to provide novel treatment options for patients battling cancer and autoimmune diseases. With strong financial backing from both Australia and France, Immutep is primed for strategic growth and medical breakthroughs.
About Immutep Limited
As a late-stage biotechnology leader, Immutep is at the forefront of developing groundbreaking immunotherapeutic solutions. The company concentrates on Lymphocyte Activation Gene-3 (LAG-3), a vital target that can stimulate or suppress the immune response. This targeted approach positions Immutep uniquely within the biotechnology landscape, as they continue to innovate and enhance treatment options for patients. Their commitment extends not only to patient care but also to maximizing shareholder value.
Engagement with Investors
Immutep is dedicated to transparent communication with its investors and the public. For Australian inquiries, Eleanor Pearson from Sodali & Co is available at +61 (0)400 886 722 or via email. Meanwhile, U.S. investors can reach out to Chris Basta, VP of Investor Relations, at +1 (631) 318 4000. Such open lines of communication facilitate an informed and engaged investment community.
Frequently Asked Questions
What is the Crédit d’Impôt Recherche?
The Crédit d’Impôt Recherche is a French government initiative that reimburses companies up to 30% of eligible R&D expenses, encouraging innovation.
How much incentive did Immutep receive?
Immutep has secured a cash incentive of approximately A$4.57 million from the French government for its research and development efforts.
What will the funds be used for?
The funds will support the ongoing clinical development of Immutep's therapies, specifically eftilagimod alfa and IMP761, aimed at treating cancer and autoimmune diseases.
How is Immutep funded in Australia?
Immutep qualifies for additional funding through the Australian Federal Government’s R&D tax incentive program in accordance with their eligible R&D activities conducted in Australia.
Who can investors contact for more information?
Interested investors can reach out to Eleanor Pearson for Australian inquiries and Chris Basta for U.S. inquiries to stay updated on the company's progress and opportunities.
